Trust Co. of Vermont Has $801,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Trust Co. of Vermont cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,550 shares of the biopharmaceutical company’s stock after selling 423 shares during the quarter. Trust Co. of Vermont’s holdings in Gilead Sciences were worth $801,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of GILD. Bleakley Financial Group LLC boosted its holdings in shares of Gilead Sciences by 9.2% during the third quarter. Bleakley Financial Group LLC now owns 23,070 shares of the biopharmaceutical company’s stock worth $1,934,000 after purchasing an additional 1,947 shares during the period. Global Retirement Partners LLC boosted its stake in shares of Gilead Sciences by 11.9% during the 3rd quarter. Global Retirement Partners LLC now owns 8,788 shares of the biopharmaceutical company’s stock valued at $737,000 after buying an additional 933 shares during the period. Good Life Advisors LLC grew its holdings in shares of Gilead Sciences by 161.3% during the 3rd quarter. Good Life Advisors LLC now owns 11,616 shares of the biopharmaceutical company’s stock valued at $974,000 after acquiring an additional 7,171 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter worth $25,000. Finally, Probity Advisors Inc. raised its holdings in shares of Gilead Sciences by 10.9% during the third quarter. Probity Advisors Inc. now owns 15,202 shares of the biopharmaceutical company’s stock worth $1,275,000 after acquiring an additional 1,496 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.7 %

Shares of Gilead Sciences stock opened at $86.72 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company’s fifty day simple moving average is $81.06 and its 200-day simple moving average is $72.80. The company has a market cap of $108.04 billion, a price-to-earnings ratio of 240.89, a PEG ratio of 2.98 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.55%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analyst Ratings Changes

A number of research analysts have commented on GILD shares. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a research note on Monday, July 8th. Truist Financial lifted their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $78.00 to $100.00 in a research report on Monday, October 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price target on shares of Gilead Sciences in a research report on Wednesday, September 11th. Ten investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.37.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.